WallStreetZenWallStreetZen

NASDAQ: SYRS
Syros Pharmaceuticals Inc Stock

$7.04-0.41 (-5.5%)
Updated Feb 21, 2024
SYRS Price
$7.04
Fair Value Price
N/A
Market Cap
$148.31M
52 Week Low
$2.09
52 Week High
$8.17
P/E
8.19x
P/B
4.09x
P/S
12.57x
PEG
0.06x
Dividend Yield
N/A
Revenue
$8.80M
Earnings
-$104.96M
Gross Margin
100%
Operating Margin
-1,137.46%
Profit Margin
-1,193.5%
Debt to Equity
3.07
Operating Cash Flow
-$122M
Beta
1.15
Next Earnings
Feb 29, 2024
Ex-Dividend
N/A
Next Dividend
N/A

SYRS Overview

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SYRS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SYRS ($7.04) is trading below its intrinsic value of $49.05, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SYRS is good value based on its earnings relative to its share price (8.19x), compared to the US market average (28.8x)
P/E vs Market Valuation
SYRS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more SYRS due diligence checks available for Premium users.

Be the first to know about important SYRS news, forecast changes, insider trades & much more!

SYRS News

Valuation

SYRS fair value

Fair Value of SYRS stock based on Discounted Cash Flow (DCF)
Price
$7.04
Fair Value
$29.38
Undervalued by
76.04%
SYRS ($7.04) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

SYRS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
8.19x
Industry
16.04x
Market
28.8x
SYRS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
SYRS is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

SYRS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.09x
Industry
5.97x
SYRS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SYRS price to earnings growth (PEG)

For valuing profitable companies with growth potential
SYRS is good value based... subscribe to Premium to read more.
PEG Value Valuation

SYRS's financial health

Profit margin

Revenue
$3.8M
Net Income
-$40.1M
Profit Margin
-1,067.1%
SYRS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SYRS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$147.8M
Liabilities
$111.5M
Debt to equity
3.07
SYRS's short-term assets ($122.52M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SYRS's short-term assets ($122.52M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SYRS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SYRS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$31.9M
Investing
$28.6M
Financing
-$5.0k
SYRS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SYRS vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
SYRS$148.31M-5.50%8.19x4.09x
MOLN$145.79M-0.22%-2.18x0.67x
XFOR$145.38M-2.58%-1.24x2.15x
DSGN$151.77M+2.26%-2.08x0.53x
SGMT$144.07M-3.44%N/A1.47x

Syros Pharmaceuticals Stock FAQ

What is Syros Pharmaceuticals's quote symbol?

(NASDAQ: SYRS) Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol SYRS. Syros Pharmaceuticals stock quotes can also be displayed as NASDAQ: SYRS.

If you're new to stock investing, here's how to buy Syros Pharmaceuticals stock.

What is the 52 week high and low for Syros Pharmaceuticals (NASDAQ: SYRS)?

(NASDAQ: SYRS) Syros Pharmaceuticals's 52-week high was $8.17, and its 52-week low was $2.09. It is currently -13.83% from its 52-week high and 236.84% from its 52-week low.

How much is Syros Pharmaceuticals stock worth today?

(NASDAQ: SYRS) Syros Pharmaceuticals currently has 21,067,071 outstanding shares. With Syros Pharmaceuticals stock trading at $7.04 per share, the total value of Syros Pharmaceuticals stock (market capitalization) is $148.31M.

Syros Pharmaceuticals stock was originally listed at a price of $181.50 in Jun 30, 2016. If you had invested in Syros Pharmaceuticals stock at $181.50, your return over the last 7 years would have been -96.12%, for an annualized return of -37.14% (not including any dividends or dividend reinvestments).

How much is Syros Pharmaceuticals's stock price per share?

(NASDAQ: SYRS) Syros Pharmaceuticals stock price per share is $7.04 today (as of Feb 21, 2024).

What is Syros Pharmaceuticals's Market Cap?

(NASDAQ: SYRS) Syros Pharmaceuticals's market cap is $148.31M, as of Feb 23, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Syros Pharmaceuticals's market cap is calculated by multiplying SYRS's current stock price of $7.04 by SYRS's total outstanding shares of 21,067,071.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.